How should the diabetes treatment be adjusted for a patient with an A1c of 9.9% who is currently taking insulin glargine (Lantus) 54 units daily, metformin 1000 mg twice daily, and glipizide 7.5 mg twice daily?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Immediate Treatment Adjustment Required

This patient with A1c 9.9% on triple therapy requires immediate treatment intensification—specifically, discontinue glipizide, continue metformin, increase Lantus to 60 units daily (10% increase), and add a GLP-1 receptor agonist such as semaglutide or dulaglutide. 1

Why This Approach

The Core Problem

Your patient is significantly above goal on maximal oral therapy plus substantial basal insulin. The A1c of 9.9% indicates therapeutic failure of the current regimen, and the 2025 ADA Standards explicitly state that treatment intensification should not be delayed (therapeutic inertia) 1.

Step 1: Remove the Glipizide

  • Glipizide (sulfonylurea) should be discontinued because:
    • It increases hypoglycemia risk without cardiovascular benefit
    • It promotes weight gain
    • When combined with basal insulin at this dose (54 units), the hypoglycemia risk is substantial
    • The patient has already failed this combination, indicating it's inadequate 1

Step 2: Optimize Basal Insulin

The current Lantus dose of 54 units can be increased using evidence-based titration:

  • Increase by 2 units every 3 days until fasting plasma glucose reaches goal (typically <100-130 mg/dL depending on individualized targets) 1
  • For hypoglycemia, reduce dose by 10-20% 1
  • The FDA label supports individualized dosing adjustments 2

However, at 54 units daily, you should evaluate for overbasalization—signs include elevated bedtime-to-morning glucose differential, hypoglycemia, or high glucose variability despite high basal doses 1.

Step 3: Add GLP-1 Receptor Agonist (Critical)

This is the most important intervention. The 2025 guidelines are explicit:

  • GLP-1 RAs or dual GIP/GLP-1 RAs typically reduce A1c by 1-2% when added to metformin 1
  • They provide cardiovascular and kidney protection independent of A1c 1
  • They cause weight loss rather than weight gain
  • Lower hypoglycemia risk compared to intensifying insulin alone
  • Should be started BEFORE further insulin intensification in patients not already on these agents 1

Specific options:

  • Semaglutide (weekly injection or daily oral)
  • Dulaglutide (weekly injection)
  • Tirzepatide (dual GIP/GLP-1 RA, weekly injection)—if available and appropriate

Step 4: Continue Metformin

Metformin must be continued unless contraindicated—it reduces all-cause mortality and cardiovascular events 1. The current dose of 1000 mg twice daily is appropriate.

Alternative Consideration: Prandial Insulin

If GLP-1 RA is not accessible or appropriate, the guidelines provide a pathway for adding prandial insulin 1:

  • Start with 4 units of rapid-acting insulin with the largest meal
  • Titrate by 1-2 units or 10-15% based on postprandial glucose
  • This addresses postprandial hyperglycemia that basal insulin alone cannot control

However, GLP-1 RA is strongly preferred over prandial insulin intensification because it avoids weight gain and hypoglycemia while providing cardiorenal benefits 1.

Monitoring and Titration Schedule

Reassess in 3 months (not 6 months given the severity) 1:

  • Check A1c, fasting glucose, and postprandial glucose patterns
  • Assess for hypoglycemia (prescribe glucagon for emergencies) 1
  • Monitor weight and cardiovascular risk factors
  • Evaluate medication adherence and barriers

Common Pitfalls to Avoid

  1. Don't just increase insulin without addressing the regimen composition—this patient is likely overbasalized already at 54 units
  2. Don't continue glipizide—it adds hypoglycemia risk without adequate benefit at this stage
  3. Don't delay GLP-1 RA addition—the guidelines explicitly recommend these agents before further insulin intensification 1
  4. Don't accept therapeutic inertia—A1c 9.9% requires immediate action, not gradual adjustments 1

If Cost is a Barrier

If GLP-1 RAs are prohibitively expensive:

  • Consider SGLT2 inhibitors (also provide cardiorenal benefits, typically reduce A1c by 0.7-1.0%) 1
  • As a last resort, proceed with prandial insulin intensification as outlined above 1
  • Discuss patient assistance programs for GLP-1 RAs given their superior benefit profile

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.